Reports Q2 revenue $1.278B, consensus $1.26B. “Our continued growth speaks to the breadth and depth of our portfolio and is driven by a mix of hero products and a steady stream of new introductions around the world,” said Brent Saunders, chairman and CEO, Bausch + Lomb (BLCO). “Our robust pipeline represents the future of the company, and we’re excited to showcase potential gamechangers at our November 13 investor day.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLCO:
- Bausch + Lomb Confirms Efficacy of LUMIFY Preservative Free Eye Drops
- Bausch + Lomb publishes Lumify eye drops data in Ophthalmology and Therapy
- Bausch + Lomb Amends CEO Employment Agreement
- Bausch + Lomb price target raised to $15 from $13 at Citi
- Mixed Product Performance and Market Challenges Justify Hold Rating for Bausch + Lomb